Science with Purpose
“Over the past four years, we’ve focused on implementing our strategy, and we’re seeing how well it is paying off. We’ve delivered new medicines that benefit patients who would otherwise have few or no treatment options while also delivering four years of consecutive growth.”
Highlights in 2024
Ipsen received regulatory approvals from the FDA and the European Commission for three first- or best-in-class medicines for five diseases.
Our production site in Dublin, Ireland received the Gold Shingo Prize for operational excellence, making us the first pharmaceutical company to receive two such awards.
We hosted our first-ever Supplier Sustainability Day, where we worked with our suppliers to identify new ways to reduce emissions across our entire value chain
2024 Key performance indicators
Total sales
Sales growth*
*at constant exchange rates (CER)
Investment in R&D
Available firepower for R&D pipeline expansion
Core operating margin
Executing our strategy in 2024
The four pillars of our strategy provide a solid foundation for our operational excellence and science-led innovation, and enable us to create real impact.
Innovation
We work relentlessly to bring the full potential of our innovative medicines to patients. This means ensuring access to medicines through regulatory excellence and robust manufacturing processes; and focusing on research and development to identify new potential indications for our medicines.
Sustainable pipeline
We build a high-value sustainable pipeline through an R&D approach that combines internal and external innovation through strategic partnerships. We leverage our end-to-end capabilities to take each molecule through each stage of development, bringing those that succeed as quickly and efficiently as possible to patients.
Efficiencies
We deliver efficiencies to enable targeted investment and growth. We evaluate all activities to ensure they will have an impact for patients and identify potential efficiencies. These are reinvested in R&D, fuel our firepower for external innovation, and support our launch activities.
Culture
We boost a culture of collaboration and excellence. Together, we are Generation Ipsen, a global team united behind our common mission of delivering science with purpose. We prioritize the well-being and health of each member of our teams.
Our people, focused on patients
Patients motivate our people to deliver science with purpose.
Meet Eva Luna
Eva Luna is an energetic little girl who loves to dance and play dress up. She also lives with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease that causes severe itch and can lead to liver failure.
Meet Anu
Anu is the Head of Oncology External Innovation at Ipsen. She and her team work at the forefront of new science and modalities in cancer care.
Meet Crystel
Crystel has worked in biomarkers for her entire career. She is proud to contribute to our portfolio of targeted treatments and to increase our expertise in companion diagnostics as our Clinical Biomarker Director.
Meet Gill
Gill, from Nottinghamshire, is devoted to her grandchildren and her garden. She spends her days with her husband and her friends. For more than 20 years, Gill has lived with primary biliary cholangitis (PBC).
Meet Diana
Diana lives in Portugal with her husband and children. When she was 34, she experienced a stroke that left her with spasticity, a condition that causes muscles to become stiff or contract involuntarily.
Therapeutic areas
We focus on three therapeutic areas: Oncology, including complex tumors and rare cancers, Rare Disease such as rare liver and bone conditions, and Neuroscience with innovations in neurotoxins.
Oncology
We pioneer treatments in cancer, advancing bold science where patients have few or no options.
Rare Disease
We are breaking new ground in rare bone and liver diseases, delivering solutions that modify the course of rare diseases and improve the often-debilitating symptoms that impact daily life.
Neuroscience
We are pushing the boundaries of science to deliver neurotoxin innovations, bringing hope to those living with debilitating neurological conditions.
